LIXT supply chain intelligence for Lixte Biotechnology Holdings, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Lixte Biotechnology Holdings, Inc. (LIXT) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| SPARTAN-CAPITAL-SECURITIES-LLC | SPARTAN-CAPITAL-SECURITIES-LLC | 92% | The Company engaged Spartan Capital Securities, LLC (the “Placement Agent”) to act as the Company’s exclusive placement agent in connection with the Offering. |
| FIVE-VENDORS-AND-CONSULTANTS | FIVE-VENDORS-AND-CONSULTANTS | 90% | Research and development costs for the three months ended March 31, 2025 include charges from five vendors and consultants representing 30.7 %, 17.1 %, 15.3 %, 15.1 % and 14.7 %, respectively, of tot… |
| LEGAL-FIRMS | LEGAL-FIRMS | 90% | General and administrative costs for the three months ended March 31, 2026 and 2025 include charges from legal firms and other vendors for general licensing and patent prosecution costs relating to t… |
| LIORA-TECHNOLOGIES-EUROPE-LTD | LIORA-TECHNOLOGIES-EUROPE-LTD | 90% | the Company, Liora and the Consultant entered into a Consultancy Agreement |
| NATIONAL-CANCER-INSTITUTE | NATIONAL-CANCER-INSTITUTE | 90% | Effective February 23, 2024, we entered into a Patent License Agreement with the National Cancer Institute |
| NATIONAL-INSTITUTE-OF-NEUROLOGICAL-DISORDERS-AND | NATIONAL-INSTITUTE-OF-NEUROLOGICAL-DISORDERS-AND | 90% | Effective February 23, 2024, we entered into a Patent License Agreement with the National Institute of Neurological Disorders and Stroke |
| ORBIT-CAPITAL-INC | ORBIT-CAPITAL-INC | 90% | In connection with the Original SEA, the Company had acquired 100% of Liora and in connection therewith had issued 2,700 shares of its Series C Preferred Stock and entered into a Royalty Agreement wi… |
| OTHER-VENDORS | OTHER-VENDORS | 90% | General and administrative costs for the three months ended March 31, 2026 and 2025 include charges from legal firms and other vendors for general licensing and patent prosecution costs relating to t… |
| TWO-MAJOR-VENDORS | TWO-MAJOR-VENDORS | 90% | Research and development costs for the three months ended March 31, 2026 include charges from two major vendors representing 90.6 % , of total research and development costs. |
| VENDOR-AND-CONSULTANT | VENDOR-AND-CONSULTANT | 90% | General and administrative costs for the three months ended March 31, 2026 includes charge from a vendor and consultant of 20 % and 30 % respectively, of total general and administrative costs. |
| SIDNEY-BRUAN | SIDNEY-BRUAN | 85% | the Consultant will be paid a signing bonus of GBP 50,000 exclusive of VAT and a monthly retainer of GBP 25,000 exclusive of VAT |
| GSK | GSK plc | 80% | Reciprocal relationship from GSK graph: Reciprocal relationship from LIXT graph: the Company issued a press release announcing it is expanding its collaboration with The University of Texas MD Anders… |
| GSK | GSK plc | 80% | the Company issued a press release announcing it is expanding its collaboration with The University of Texas MD Anderson Cancer Center, Northwestern University, and pharmaceutical manufacturer GSK |
| MANAGEMENT-REPRESENTATION | MANAGEMENT-REPRESENTATION | 80% | General and administrative costs for the three months ended March 31, 2026 also include charges for management representation representing 7.29 % of total general and administrative costs. |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ANDERSON-CANCER-CENTER | ANDERSON-CANCER-CENTER | 90% | In consideration of the Anderson Cancer Center conducting the Expanded Study at its costs, the Company will pay the Anderson Cancer Center milestone payments |
| THE-UNIVERSITY-OF-TEXAS-MD-ANDERSON-CANCER-CENTE | THE-UNIVERSITY-OF-TEXAS-MD-ANDERSON-CANCER-CENTE | 90% | In consideration of the Anderson Cancer Center conducting the Expanded Study at its costs, the Company will pay the Anderson Cancer Center milestone payments |
| GSK | GSK plc | 85% | the Company issued a press release announcing it is expanding its collaboration with The University of Texas MD Anderson Cancer Center, Northwestern University, and pharmaceutical manufacturer GSK |
| GSK | GSK plc | 85% | Reciprocal relationship from GSK graph: Reciprocal relationship from LIXT graph: Reciprocal relationship from GSK graph: Reciprocal relationship from LIXT graph: the Company issued a press release an… |
| ORBIT-CAPITAL-INC | ORBIT-CAPITAL-INC | 85% | Additionally, on December 30, 2025, the Company and Orbit entered into a Share Exchange Agreement (the "Post-Closing SEA"), whereby Orbit exchanged 2,700 shares of the Company’s Series C Preferred St… |
| NORTHWESTERN-UNIVERSITY | NORTHWESTERN-UNIVERSITY | 80% | the Company issued a press release announcing it is expanding its collaboration with The University of Texas MD Anderson Cancer Center, Northwestern University, and pharmaceutical manufacturer GSK |
| DR-ASHER-SCHMULEWITZ-CONTEMPORANEOUSLY-ORBIT-CAP | DR-ASHER-SCHMULEWITZ-CONTEMPORANEOUSLY-ORBIT-CAP | 62% | eral licensing and patent prosecution costs relating to the Company’s intellectual properties representing 2.9 % and 8.6 % of total general and administrative costs, respectively. General and adminis… |
| LIORA-TECHNOLOGIES-EUROPE-LTD | LIORA-TECHNOLOGIES-EUROPE-LTD | 62% | eral licensing and patent prosecution costs relating to the Company’s intellectual properties representing 2.9 % and 8.6 % of total general and administrative costs, respectively. General and adminis… |
| SPARTAN-CAPITAL-SECURITIES-LLC | SPARTAN-CAPITAL-SECURITIES-LLC | 62% | . The Company sold and issued 434,784 shares of common stock at $ 2.415 per share. In a concurrent private placement, the Company also issued warrants to purchase 434,784 shares of common stock at an… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| LIXT-DEBT-10728 | Warrants outstanding: 113310 | 90% | xbrl warrant detail from xbrl 2026-03-31. |
| LIXT-DEBT | Debt stack $1.0M | 90% | Market cache reports total debt of $1.0M. |
| LIXT-DEBT-10729 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2026-03-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| LIXT-OWNER-SCOTIA-CAPITAL-INC | SCOTIA CAPITAL INC. | 90% | 13F overlay lists SCOTIA CAPITAL INC. as top holder; 14 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 2 | |
| BDRX | Biodexa Pharmaceuticals Plc | 100.00 | 2 | |
| DEO | Diageo plc | 100.00 | 2 | |
| BCAX | Bicara Therapeutics Inc. | 100.00 | 2 | |
| LEGN | Legend Biotech Corporation | 100.00 | 2 | |
| SMMT | Summit Therapeutics Inc. | 100.00 | 2 | |
| PCVX | Vaxcyte, Inc. | 100.00 | 2 | |
| GSK | GSK plc | 54.19 | 1 | ['customer', 'supplier'] |
| ZYME | Zymeworks Inc. | 50.00 | 2 | |
| SPRO | Spero Therapeutics, Inc. | 50.00 | 2 | |
| GNTA | Genenta Science S.p.A. | 50.00 | 2 | |
| TBPH | Theravance Biopharma, Inc. | 50.00 | 2 | |
| TRVI | Trevi Therapeutics, Inc. | 50.00 | 2 | |
| HLN | Haleon plc | 50.00 | 2 | |
| INVA | Innoviva, Inc. | 50.00 | 2 | |
| SJM | The J. M. Smucker Company | 50.00 | 2 | |
| NEXN | Nexxen International Ltd. | 50.00 | 2 | |
| SCYX | SCYNEXIS, Inc. | 50.00 | 2 | |
| GLAXF | GSK plc | 50.00 | 2 | |
| ZBIO | Zenas BioPharma, Inc. | 50.00 | 2 |